NEW YORK, May 18, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Vascular Biogenics Ltd. (NASDAQ: VBLT), Alexza Pharmaceuticals Inc. (NASDAQ: ALXA), TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG), and Cleveland BioLabs, Inc. (NASDAQ: CBLI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CRBP Research Report: ( http://get.analystsreview.com/pdf/?c=Corbus&d=18-May-2015&s=CRBP ),
VBLT Research Report: ( http://get.analystsreview.com/pdf/?c=Vascular%20Biogenics&d=18-May-2015&s=VBLT ),
ALXA Research Report: ( http://get.analystsreview.com/pdf/?c=Alexza&d=18-May-2015&s=ALXA ),
TLOG Research Report: ( http://get.analystsreview.com/pdf/?c=TetraLogic&d=18-May-2015&s=TLOG ),
CBLI Research Report: ( http://get.analystsreview.com/pdf/?c=Cleveland%20BioLabs&d=18-May-2015&s=CBLI ).
Analyst Update: Financial and Operational Results, Clinical Trials and Business Updates
U.S. stocks mostly drifted between modest gains and losses on Friday, May 15, 2015 as investors remained cautious over weaker than expected economic data. The Dow Jones Industrial Average gained 0.11%, to finish at 18,272.56, the S&P 500 rose 0.08%, to 2,122.73, and the NASDAQ Composite ended the day at 5,048.29, down 0.05%. European stocks closed lower on Friday amid rise in the value of euro against dollar. Germany's DAX 30 lost 0.98%, France's CAC 40 fell 0.71%, and London's FTSE 100 closed 0.18% lower on Friday. Meanwhile, Asian markets painted a mixed picture on Friday. The Shanghai Composite fell as expectation of Chinese stimulus measures cooled, while Hong Kong's Hang Seng and Japan's Nikkei gained on Friday.
On May 13, 2015, Corbus Pharmaceuticals Holdings, Inc. announced its financial and operational results along with business updates for the first quarter of 2015. The Company announced that it received a $5 million development award from Cystic Fibrosis Foundation Therapeutics (CFFT) to advance Resunab into a Phase 2 clinical trial for CF.
On May 13, 2015 Vascular Biogenics Ltd, conducting business under the name VBL Therapeutics Ltd, announced that principal investigator, Richard Penson, M.D., M.R.C.P., will be presenting interim data from the Company's ongoing Phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Müllerian cancer, in a poster presentation on Saturday, May 30, 2015 at the American Society for Clinical Oncology (ASCO) 2015 Annual Meeting.
Alexza Pharmaceuticals, Inc. reported its financial results and also provided business updates for the first quarter of 2015. Alexza recorded revenues of $0.7 million for the quarter as comparted to revenues of $2.2 million in Q1 2014.
TetraLogic Pharmaceuticals Corporation announced that two research papers describing birinapant's preclinical activity in a mouse model of chronic human hepatitis B virus (HBV) has been published in the journal Proceedings of the National Academy of Sciences: "Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus" and "Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis".
On May 6, 2015 Cleveland BioLabs, Inc. announced its financial results and development progress for the first quarter of 2015. Revenue decreased to $0.6 million from $1.3 million for the first quarter of 2014, due to the deconsolidation of Incuron LLC in Q4 2014 and reduced Mobilan grant income, as it awaited approval to commence a Phase 1 trial.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review